vaccine candidate for the novel coronavirus have shared results from their preliminary and late-stage trials, touting high efficacy rates of 90 per cent and above.Moderna first released its results on Nov.
16, claiming its vaccine candidate was 94.5 per cent effective against COVID-19, based on preliminary data from an ongoing study.
Pfizer followed shortly after, announcing two days later that its candidate was 95 per cent effective based on a final analysis from its Phase 3 clinical trial.On Monday, AstraZeneca joined them, touting a combined efficacy rate of 70 per cent based on one dosing regimen that proved 90 per cent effective and another that was 62 per cent effective.